ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)
Public ClinicalTrials.gov record NCT01382797. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose Study to Evaluate the Safety, Tolerability, and Efficacy of ALKS 37 in Subjects With Opioid-induced Constipation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety, tolerability and efficacy of ALKS 37 when administered daily for 4 weeks to adults with Opioid-induced Constipation (OIC).
Study identification
- NCT ID
- NCT01382797
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 157 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2011 (Type not available)
- Primary completion
- Apr 2012 (Actual)
- Completion
- Apr 2012 (Actual)
- Last update posted
- Jun 13, 2012
2011 – 2012
United States locations
- U.S. sites
- 20
- U.S. states
- 15
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alkermes Study Site | Mesa | Arizona | 85206 | — |
| Alkermes Study Site | Phoenix | Arizona | 85053 | — |
| Alkermes Study Site | National City | California | 91950 | — |
| Alkermes Study Site | Oceanside | California | 92056 | — |
| Alkermes Study Site | Pasadena | California | 91105 | — |
| Alkermes Study Site | Denver | Colorado | 80211 | — |
| Alkermes Investigational Site | DeLand | Florida | 32724 | — |
| Alkermes Study Site | Ormond Beach | Florida | 32174 | — |
| Alkermes Study Site | St. Petersburg | Florida | 33709 | — |
| Alkermes Study Site | Stockbridge | Georgia | 30281 | — |
| Alkermes Study Site | Boise | Idaho | 83704 | — |
| Alkermes Study Site | New Orleans | Louisiana | 70114 | — |
| Alkermes Study Site | Kalamazoo | Michigan | 49009 | — |
| Alkermes Study Site | Las Vegas | Nevada | 89144 | — |
| Alkermes Study Site | Belvidere | New Jersey | 07823 | — |
| Alkermes Study Site | Brooklyn | New York | 11218 | — |
| Alkermes Study Site | Cincinnati | Ohio | 45224 | — |
| Alkermes Study Site | Oklahoma City | Oklahoma | 73134 | — |
| Alkermes Study Site | Medford | Oregon | 97504 | — |
| Alkermes Study Site | San Antonio | Texas | 78228 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01382797, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 13, 2012 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01382797 live on ClinicalTrials.gov.